公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2019 | Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis | Yau T.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M. | Journal of Hepatology | 168 | 154 | |
2017 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L.; Neely J.; Tang H.; Dastani H.B.; Melero I. | The Lancet | 3010 | 2816 | |
2024 | Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040 | El-Khoueiry, A B; Trojan, J; Meyer, T; Yau, T; Melero, I; Kudo, M; CHIUN HSU ; Kim, T-Y; Choo, S-P; Kang, Y-K; Yeo, W; Chopra, A; Soleymani, S; Yao, J; Neely, J; Tschaika, M; Welling, T H; Sangro, B | Annals of oncology : official journal of the European Society for Medical Oncology | | | |
2020 | Novel systemic therapy for hepatocellular carcinoma | Dong Y.; TSUNG-HAO LIU ; Yau T.; CHIUN HSU | Hepatology International | 13 | 11 | |
2009 | Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival | Ying-Chun Shen ; Hu F.-C.; YUNG-MING JENG ; YU-TING CHANG ; ZHONG-ZHE LIN ; MING-CHU CHANG ; CHIUN HSU ; ANN-LII CHENG | Cancer Epidemiology Biomarkers and Prevention | 21 | 20 | |
2020 | An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas | Chen M.-H.; Chou W.-C.; Hsiao C.-F.; Jiang S.S.; Tsai H.-J.; Liu Y.-C.; CHIUN HSU ; Shan Y.-S.; Hung Y.-P.; Hsich C.-H.; Chiu C.-H.; Liu T.-C.; Cho S.-F.; Liu T.-W.; Chao Y. | Oncologist | 7 | 6 | |
2008 | Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment | ZHONG-ZHE LIN ; CHIUN HSU ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HUNG HSU ; CHIA-CHI LIN ; ANN-LII CHENG ; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 5 | 1 | |
2009 | Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma | Jan Y.-J.; BOR-SHENG KO ; CHIUN HSU ; Chang T.-C.; Chen S.-C.; Wang J.; Liou J.-Y. | Human Pathology | 28 | 27 | |
2011 | Overexpression of 14-3-3ε predicts tumour metastasis and poor survival in hepatocellular carcinoma | BOR-SHENG KO ; Chang T.-C.; CHIUN HSU ; YAO-CHANG CHEN ; Shen T.-L.; Chen S.-C.; Wang J.; Wu K.K.; Jan Y.-J.; Liou J.-Y. | Histopathology | 48 | 46 | |
2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | Chen L.-T.; Martinelli E.; ANN-LII CHENG ; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; CHIUN HSU ; YING-CHUN SHEN ; Tabernero J.; Yen Y.; CHIH-HUNG HSU ; Yoshino T.; Douillard J.-Y. | Annals of Oncology | 117 | 112 | |
2020 | Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study | Mehnert J.M.; Bergsland E.; O’Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; CHIUN HSU ; Le Tourneau C.; Hollebecque A.; Élez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A. | Cancer | 83 | 75 | |
2023 | Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial | Kelley, Robin Kate; Ueno, Makoto; Yoo, Changhoon; Finn, Richard S; Furuse, Junji; Ren, Zhenggang; Yau, Thomas; Klümpen, Heinz-Josef; Chan, Stephen L; Ozaka, Masato; Verslype, Chris; Bouattour, Mohamed; Park, Joon Oh; Barajas, Olga; Pelzer, Uwe; Valle, Juan W; Yu, Li; Malhotra, Usha; Siegel, Abby B; Edeline, Julien; Vogel, Arndt; CHIUN HSU | Lancet (London, England) | 111 | | |
2015 | Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide | PO-CHIN LIANG ; Ch’ang H.-J.; CHIUN HSU ; Chen L.-T.; TIFFANY TING-FANG SHIH ; Liu T.W. | Hepatology International | 13 | 12 | |
2016 | Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer | SHIH-HUNG YANG ; TING-CHUN KUO ; Wu H.; JHE-CYUAN GUO ; CHIUN HSU ; CHIH-HUNG HSU ; YU-WEN TIEN ; KUN-HUEI YEH ; ANN-LII CHENG ; SUNG-HSIN KUO | World Journal of Gastroenterology | 24 | 25 | |
2006 | Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer | Ch'ang H.-J.; Wang C.-C.; ANN-LII CHENG ; CHIUN HSU ; YEN-SHEN LU ; MING-CHU CHANG ; Lin J.-T.; HSIU-PO WANG ; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. | Journal of Gastroenterology and Hepatology (Australia) | 8 | 8 | |
2006 | Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer | Shiah H.-S.; ANN-LII CHENG ; CHIUN HSU ; CHIH-HUNG HSU ; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. | Journal of Gastroenterology and Hepatology (Australia) | 6 | 5 | |
2014 | Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer | Ying-Chun Shen ; Li C.-P.; Yen C.-J.; CHIUN HSU ; Lin Y.-L.; ZHONG-ZHE LIN ; Chen L.-T.; Su W.-C.; Chao Y.; KUN-HUEI YEH ; ANN-LII CHENG | Oncology (Switzerland) | 15 | 12 | |
2004 | Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma | Lu Y.-S.; CHIUN HSU ; Li C.-C.; Kuo S.-H.; KUN-HUEI YEH ; CHIH-HSIN YANG ; CHIH-HUNG HSU ; Wu C.-Y.; ANN-LII CHENG | Hepato-Gastroenterology | 14 | 13 | |
2010 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma | CHIH-HUNG HSU ; Ying-Chun Shen ; ZHONG-ZHE LIN ; PEI-JER CHEN ; YU-YUN SHAO ; Ding Y.-H.; CHIUN HSU ; ANN-LII CHENG | Journal of Hepatology | 110 | 103 | |
2012 | Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma | Ch'Ang H.-J.; CHIUN HSU ; CHIEN-HUNG CHEN ; Chang Y.-H.; Chang J.S.; Chen L.-T. | International Journal of Radiation Oncology Biology Physics | 16 | 13 | |